Nasdaq:US$14.04 (-0.18) | HKEX:HK$21.66 (-0.30) | AIM:£2.06 (-0.03)
搜索
新闻中心及演示文稿
上一篇文章   |   下一篇文章
演示文稿, 科学出版物 | 2013-04-06

AACR 2013: HMPL-504 (savolitinib), a novel, selective and potent cMET inhibitor, is efficacious in primary tumor models of cMET-driven gastric cancer